# Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

> **NCT04866862** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 32 (estimated)

## Conditions studied

- Colorectal Neoplasm

## Interventions

- **DRUG:** Combination of Fruquintinib and Camrelizumab

## Key facts

- **NCT ID:** NCT04866862
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-26
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866862, "Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04866862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*